Trial Condition(s):
Exit interviews to assess impact of infusion frequency in Hemophilia A
This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients’ satisfaction with treatment and their quality of life.
- Patient is enrolled in the BAY94-9027 extension studies or is within 3 months of having completed participation in the BAY94-9027 extension studies; - Patient allocated to Arm 2, Arm 3 or Arm 4 of BAY94-9027 extension studies. -- Arm 2 Prophylaxis treatment of BAY94-9027; 2 infusions per week during the extension study --Arm 3 Prophylaxis treatment of BAY94-9027; infusion every 5 days during the extension study --Arm 4 Prophylaxis treatment of BAY94-9027; every 7 days during the extension study - Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study; - Patient must be willing and able to participate in a telephone interview lasting up to 30 minutes; - Patient must have sufficient cognitive and linguistic capacities to allow them to actively participate in an interview lasting 30 minutes.
- Patient is part of Arm 1: On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds; - Patient is unlikely to comply with the study protocol (e.g. uncooperative attitude) or unlikely to complete the study for any reason in the opinion of the recruiter; - Patient has great difficulty hearing or reading; - Patient has any significant comorbid condition (including uncontrolled psychiatric conditions) that might limit or interfere with their ability to talk about their Hemophilia A and participate in the study; - Patient has severe neurological or cognitive deficits that might affect their ability to participate in an interview.
Locations | Status | ||
---|---|---|---|
Locations Cleveland Cleveland, United States, 110605 | Status Completed | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Exit interviews to assess impact of infusion frequency in Hemophilia A
Trial Type:
Observational
Intervention Type:
Biological/Vaccine
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
3
Not Available